Skip to main content

Unresectable Chordoma clinical trials at UC Health
1 research study open to eligible people

  • Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

    open to eligible people ages 12 years and up

    This phase II trial studies how well nivolumab and relatlimab work in treating participants with chordoma that has spread to other places in the body. Monoclonal antibodies, such as nivolumab and relatlimab, may interfere with the ability of tumor cells to grow and spread.

    at UCLA

Last updated: